Outlook Therapeutics Inc. Stock News

Outlook Therapeutics (NASDAQ: OTLK ) stock is taking a beating on Wednesday after getting a rejection letter from the FDA. That letter has to do with its biologics license application (BLA) for ONS-5

Outlook Therapeutics Inc (NASDAQ:OTLK) stock collapsed, losing some 70% of its value in premarket, after the drug discovery firm's potential treatment for eye disease was rejected by the US Food and D

Outlook Therapeutics said on Wednesday the U.S. Food and Drug Administration declined to approve its experimental eye disease drug, in part due to manufacturing issues observed during pre-approval ins

Outlook Therapeutics Inc.'s stock OTLK, +10.16% tumbled 71% in premarket trade Wednesday, after the company said the U.S. Food and Drug Administration has issued a Control Response Letter for the comp

Outlook Therapeutics (OTLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevac

OTLK is developing an ophthalmic formulation of bevacizumab. There is a logic behind this, and there's also positive data. However, certain developments stop me from being overly enthusiastic.

Outlook, a clinical-stage biotech, is awaiting potential approval for a wet AMD therapy. The therapy has a PDUFA date of Aug. 29 from the FDA.

From a technical perspective, Oncobiologics, Inc. (OTLK) is looking like an interesting pick, as it just reached a key level of support. OTLK's 50-day simple moving average crossed above its 200-day s

Oncobiologics, born in pursuit of oncology biosimilars, dramatically shifted its outlook, appropriately rechristening itself as Outlook Pharmaceuticals. Outlook has set its sights full bore on treatme

Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in a live moderated fireside chat on Tuesday, May

Outlook Therapeutics Inc (NASDAQ:OTLK) announced that it has ended its first quarter of fiscal 2023 with cash and equivalents of $52.3 million as of December 31, 2022, which the company says is expect

Outlook Therapeutics Inc (NASDAQ:OTLK) has announced the appointments of Dr Surendra Sharma as senior vice president of medical affairs and Glen Olsheim as executive director of commercial excellence

Outlook Therapeutics Inc (NASDAQ:OTLK) has announced financial results for its fiscal year ended September 30 and laid out plans for 2023 in an end-of-year letter. “Our fiscal year 2022 laid a solid

Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into securities purchase agreements with existing institutional and accredited investors for a registered direct offering priced at-the-marke